Navigation Links
How can you heal a broken heart?
Date:4/12/2010

Montral, Qubec, Canada, April 12, 2010 - Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment. Researchers at the Research Centre of the Centre hospitalier de l'Universit de Montral (CRCHUM), in collaboration with the Maisonneuve-Rosemont Hospital (MRH) are evaluating the safety, feasibility and efficacy of injecting stem cells into the hearts of patients while they are undergoing coronary bypass surgery. These stem cells could improve healing of the heart and its function.

The IMPACT-CABG (implantation of autologous CD133+ stem cells in patients undergoing coronary artery bypass grafting) protocol evaluates this experimental procedure, which is destined for patients suffering from ischemic heart disease, in which the blood supply to the heart is decreased and associated with heart failure. These patients undergo open-heart coronary bypass surgery, performed by the medical team to improve perfusion of the heart muscle. A few weeks ago, the first patient received progenitor CD133+ stem cells isolated from his bone marrow and enriched at the Cell Therapy Laboratory of the MRH, and has been doing very well ever since. Already, improvement has been noted in the contraction capacity of his heart, which has improved its ability to pump blood.

Objective of the intervention

The IMPACT-CABG study targets a group of patients who suffer heart muscle failure due to coronary heart disease. The goal is to add another treatment option to coronary bypass to promote healing and regeneration of the damaged heart muscle. This new procedure is less invasive and less expensive than heart transplant, the only treatment now available for patients with severe heart failure. The researchers plan to recruit a total of 20 patients throughout Qubec in the first phase. A second Canadian centre, at the General Hospital of the University of Toronto, will also take part in the trial. In 2007, the CRCHUM, in collaboration with the MRH, began the COMPARE-AMI clinical trial, to evaluate the safety and feasibility of intramyocardial injection of stem cells (injecting them into the heart through a catheter) in a different group of patients who have suffered their first infarction.

A Canadian first

Before the IMPACT-CABG trial, previous studies in other countries had also evaluated the safety and feasibility of injecting different stem cells in the hearts of patients with cardiac dysfunction. This is a first study in Canada evaluating intramyocardial injection of stem cells. "Also, no research team in the country had implemented such a complete treatment process, going from harvesting stem cells in the patient, treating them, and injecting them directly into the myocardium," states Dr. Nicolas Noiseux, cardiac surgeon at the CHUM and principal investigator in the study. "Moreover, the methods used to evaluate the recovery of heart function make use of cutting-edge imaging techniques," reports Dr. Samer Mansour, cardiologist at the CHUM, principal co-investigator.

To prepare for the intervention, cells from the bone marrow harvested at the CHUM are transferred to the cell therapy laboratory of the MRH to isolate the most immature stem cells, which will be injected directly into the patient's heart. "MRH has developed a unique expertise in cellular therapy. This expertise serves cardiology in those specific cases and we hope to develop other applications to regenerate the cornea, cartilage and other tissues and organs," adds Dr. Denis Claude Roy, haematologist, Director of research and Director, Cell therapy Laboratory at MRH, and also a principal co-investigator.


'/>"/>

Contact: Nathalie Forgue
nathalie.forgue.chum@ssss.gouv.qc.ca
514-890-8000 x14342
Centre hospitalier de l'Universit de Montral
Source:Eurekalert

Related biology news :

1. Researchers determine how ATP, molecule bearing the fuel of life, is broken down in cells
2. Grandpas broken hip may mean weaker bones for his grandsons
3. New strategy for mending broken hearts?
4. Award for pioneering stem cell research to mend broken bones
5. CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die
6. Smart scaffolds may help heal broken hearts
7. Preventing a broken heart: Research aims to reduce scarring from heart attacks
8. New journal shows half-broken gene is enough to cause cancer
9. MIT: Mending broken hearts with tissue engineering
10. Music in speech equals empathy in heart?
11. Study: Fountain of youth for your heart?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... AMSTERDAM , April 20, 2017 Dutch philosopher Koert ... of ,Next Nature, at the University of Technology in Eindhoven - has ... In this letter, he calls on humanity to avoid becoming a slave and ... race. ... Dutch philosopher Koert van Mensvoort – founder of ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... A number ... advances. This webinar, which is part of the Protein and Cell Analysis Education ... and outline where this technology fits in current and future applications. , Many ...
(Date:4/19/2017)... ... 2017 , ... ThermaGenix, the PCR Improvement Company, announces the ... other early achievements at ThermaGenix, including the business formation and licensing agreements, and ... use proceeds from the Series A-1 round to:, , ...
(Date:4/19/2017)... April 19, 2017  As a Bronze ... Heroin Summit ,  Proove® Biosciences, Inc. announces ... environmental, and lifestyle factors to accurately predict prescription ... of Southern California (USC), the Interventional Pain Institute ... publish results showing that Proove Opioid Risk® accurately ...
Breaking Biology Technology: